Jagsonpal Pharmaceuticals reports Q2FY23 net profit at Rs. 10.41 Cr
The company has reported total income of Rs. 61.64 crores during the period ended September 30, 2022.
The company has reported total income of Rs. 61.64 crores during the period ended September 30, 2022.
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
ASG is accelerating its doctor-led mission to enhance the quality of care, deliver eye care for all, and improve quality of life across India.
For the half year ended September 30th, 2022 revenue from operations stood at Rs. 185.44 crore in H1 FY23, as against Rs. 219.89 crore in H1 FY22, a decrease of 15.67%
Doxycycline Capsules (RLD Oracea) had estimated annual sales of US $215 million in the US
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
The company posted net profit of Rs.81.33 crores for the quarter ended September 30, 2021.
The acquisition is for an enterprise value of Rs. 218 crores
Subscribe To Our Newsletter & Stay Updated